Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040099 · ClinicalTrials.gov registry record · Phase 2
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
A Phase 2 study of Hepatocellular Carcinoma (HCC), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT06040099: Active Phase 2 study of Hepatocellular Carcinoma (HCC), sponsored by AstraZeneca.
NCT06040099 is a Phase 2 study of Hepatocellular Carcinoma (HCC) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 58 participants, below the 347-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06040099, a Phase 2 study of Hepatocellular Carcinoma (HCC), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Primary Outcome
PFS is defined as the time from Day 1 (day of TARE) until the date of progressive disease per modified Response Evaluation Criteria in Solid Tumors (mRECIST), as assessed by the investigator, or death due to any cause. It is measured to assess the efficacy of TARE followed by durvalumab monotherapy followed by durvalumab + bevacizumab in participants with unresectable HCC amenable to locoregional therapy.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Durvalumab
- PROCEDURE Transarterial Radioembolization (TARE)
Study Locations (20)
Florida
- Research Site - Gainesville
- Research Site - Orlando
Georgia
- Research Site - Atlanta
- Research Site - Atlanta
New York
- Research Site - Buffalo
- Research Site - New York
Colorado
- Research Site - Aurora
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Detroit
Missouri
- Research Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
What the registry record for NCT06040099 still lists
NCT06040099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 347-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06040099 names 20 study sites across 17 states, led by Florida, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT06040099 about?
NCT06040099 is a clinical study titled "A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE". The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
What is the current status of trial NCT06040099?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2024-02-13. Estimated completion is 2026-07-01.
What conditions does trial NCT06040099 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).
What interventions are being tested in trial NCT06040099?
The interventions under investigation include: Bevacizumab (DRUG), Durvalumab (DRUG), Transarterial Radioembolization (TARE) (PROCEDURE).
Who is sponsoring clinical trial NCT06040099?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06040099 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma (HCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06040099's enrollment target sits among peer trials
58 13th of 15 higher than 3 of 15 other Hepatocellular Carcinoma (HCC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma (HCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
RECRUITING
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI